The previous exploration of NSCLC targets focused on the structural variation or differential expression at the molecular level among different tissues or patients, such as the identification of EGFR mutation, KRAS mutation and ALK fusion in small molecule targeted therapy [15–17]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.